President and Chief Executive Officer
Stephen S. Tang, Ph.D. became President and CEO of OraSure on April 1, 2018. Prior to becoming President and CEO, Dr. Tang joined the OraSure Board in April of 2011 and was the Company’s Chairman of the Board since November 2017. Prior to joining OraSure, Dr. Tang served as President and Chief Executive Officer of The University City Science Center, an urban research park and business incubator owned by over thirty leading universities, medical schools and health networks in the greater Philadelphia, Pennsylvania area. Prior to that, Dr. Tang held senior management and business development positions with several firms in the life sciences industry, including Olympus America, Inc., Millennium Cell Inc. and A.T. Kearney Inc. Dr. Tang holds a B.S. degree in Chemistry from The College of William and Mary, an M.S. degree and Ph.D. in Chemical Engineering from Lehigh University and an M.B.A. from The Wharton School of Business at the University of Pennsylvania.
Chief Financial Officer
Roberto Cuca joined OraSure in May 2018, initially serving as Senior Advisor to the Company until his appointment as the Company’s Chief Financial Officer in June 2018. Prior to joining OraSure, Mr. Cuca served as Senior Vice President and Chief Financial Officer of Trevena, Inc., a clinical stage biopharmaceutical company, where he led the finance and investor relations functions and worked with senior management to establish and execute overall corporate strategy. Prior to his tenure with Trevana, Mr. Cuca held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, including Treasurer and Senior Vice President, Finance, where he was responsible for capital raises and cash management, mergers, acquisitions and licensing transactions, tax planning and compliance, and risk management. Before he joined Endo, Mr. Cuca served as the Director, Corporate and Business Development at moksha8 Pharmaceuticals, Inc., an emerging markets-focused pharmaceutical company, and as an equity analyst covering U.S. pharmaceutical companies at J.P. Morgan Chase & Co. Mr. Cuca received an M.B.A. from the Wharton School of the University of Pennsylvania, a Juris Doctor from Cornell Law School, and an A.B. from Princeton University. Mr. Cuca is also a CFA Charterholder.
Executive Vice President, Business Unit Leader, Infectious Disease
Lisa Nibauer joined OraSure as Executive Vice President, Business Unit Leader, Infectious Disease in May 2020. Prior to joining OraSure, Ms. Nibauer spent eight years at BD Becton Dickinson, Inc. (“BD”), most recently as VP/GM, Global Medication Delivery Solutions. In that role, she had general management responsibility for $1.6 billion in annual revenue and a team of over 300 people globally and was also accountable for the Global Marketing function for the largest business unit in BD. Prior to that, also at BD, Ms. Nibauer held the positions of VP/GM, Global PreAnalytical Systems Business & Global Marketing and Senior Director, Global Blood Collection Acquisition Platform. Prior to joining BD, she held general management, sales and marketing positions with increasing responsibilities at Adlens Beacon Inc., Schering-Plough Consumer Healthcare (Bayer), General Mills, Elf Atochem, and ICI (now part of AstraZeneca, Henkel and AkzoNobel). Ms. Nibauer earned an M.B.A. from UCLA Anderson School of Management and a B.S. in Chemical Engineering from Lehigh University.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Jack E. Jerrett has been the Company’s Senior Vice President and General Counsel since February 2003 and served as the Vice President and General Counsel since November 2000. He has also served as the Company’s Secretary since February 2001. Prior to joining the Company, Mr. Jerrett worked as an Associate at Morgan, Lewis & Bockius and held positions of increasing legal responsibilities with companies in the transportation and energy industries. Mr. Jerrett received a B.S. degree in Accounting from Villanova University and a Juris Doctor from the Villanova University School of Law. He is a member of the Pennsylvania Bar and the American and Pennsylvania Bar Associations.
Senior Vice President, Operations
Ted Rauth has been the Senior Vice President, Operations since November 2019. Prior to joining OraSure, Mr. Rauth was the Vice President of Operations at US BioDesign. He was responsible for Production, Supply Chain, Manufacturing Engineering, Facilities & Maintenance and Quality. Prior to that, he served as Vice President of Operations at DSM BioMedical/Kensey Nash for more than 18 years. Mr. Rauth came to Kensey Nash from Merck & Co., Inc., where he worked for four and a half years and held the positions of Production Supervisor, Power Plant Superintendent and Maintenance Manager. He started his career serving in the Nuclear Navy onboard two submarines and teaching at The U.S. Submarine School. Mr. Rauth received his Bachelor’s degree from Penn State in Chemical Engineering with a minor in Math and an Honors degree from the Honors College. He continued his education and received a Master’s degree in Mechanical Engineering from Rensselaer Polytechnic Institute.
Senior Vice President, Business Development
David Rappaport has been the Senior Vice President, Business Development since April 2018. Prior to joining OraSure, Mr. Rappaport served as the Senior Vice President, Healthcare Investment Banking at Raymond James & Associates where he provided investment banking services in the Life Sciences practice group. Prior to his tenure at Raymond James, Mr. Rappaport served as a healthcare investment banker with Inverness Advisors, LLC, Thomas Weisel Partners, and SG Cowen. Mr. Rappaport received a Bachelors of Business Administration in Finance and Economics from the University of Wisconsin and an MBA from Emory University.
Executive Vice President, Business Unit Leader, Molecular Solutions
Kathleen Weber was named Executive Vice President, Business Unit Leader for Molecular Solutions in January 2019. In this role, she has oversight for the commercial, operational and financial performance of the business unit, which is also known as DNA Genotek. Kathy joined OraSure in 2012 as the Senior Vice President and General Manager, Consumer Products. Her role evolved from 2012 to 2018 to also include at various points in time managing the Emerging Disease Portfolio and leading the development of OraSure’s corporate strategy. Prior to joining OraSure, Ms. Weber held several senior commercial leadership positions at Pfizer, Johnson and Johnson and Schering–Plough. Ms. Weber began her career in the financial services industry and held various positions in U.S. and global marketing and operations at Chase Manhattan Bank, now part of JP Morgan Chase. Ms. Weber received a B.S. degree in business administration from Georgetown University and earned an M.B.A. from New York University’s Stern School of Business.